Dupilumab suppresses type 2 biomarkers of inflammation in patients with eosinophilic esophagitis: from Part B of LIBERTY-EoE-TREET

Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease of the esophagus. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation. In phase 3 LIBERTY-EoE-TREET (NCT03633617) dupilumab improved histologic, symptomatic, and endoscopic aspects of EoE and was well tolerated. This pre-specified analysis evaluates the effect of dupilumab vs placebo on type 2 biomarkers during Part B of LIBERTY-EoE-TREET.